NCT04360655 is a NA clinical trial of bronchoscopic microwave intervention in Effect Increased, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT04360655?

NCT04360655 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT04360655?

Interventions in NCT04360655: bronchoscopic microwave intervention, anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy.

What condition does NCT04360655 study?

NCT04360655 studies Effect Increased, Safety Issues.

Is NCT04360655 still recruiting?

NCT04360655 is currently status unknown. Last updated 24 April 2020.

Last reviewed 2020-04-24 · How we verify

NCT04360655

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC

Status unknown NA Last updated 24 April 2020

What this trial tests

NA trial testing bronchoscopic microwave intervention in Effect Increased in 50 participants. Status unknown.

Timeline

1 May 2020

Primary endpoint
30 April 2022

1 May 2023

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 May 2020
Primary completion	30 April 2022
Estimated completion	1 May 2023

Drugs / interventions tested

bronchoscopic microwave intervention
anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy — full drug profile →

Conditions studied

Effect Increased — all drugs for Effect Increased →
Safety Issues — all drugs for Safety Issues →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 18 to 75, any sex, with Effect Increased or Safety Issues. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04360655 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 24 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04360655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing